Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myopia | 28 | 2025 | 114 | 10.110 |
Why?
|
| Contact Lenses, Hydrophilic | 21 | 2025 | 78 | 7.600 |
Why?
|
| Refraction, Ocular | 22 | 2025 | 127 | 5.430 |
Why?
|
| Visual Acuity | 11 | 2025 | 179 | 2.740 |
Why?
|
| Accommodation, Ocular | 5 | 2023 | 36 | 2.060 |
Why?
|
| Refractive Errors | 6 | 2023 | 58 | 1.990 |
Why?
|
| Disease Progression | 11 | 2025 | 74 | 1.870 |
Why?
|
| Contact Lenses | 5 | 2021 | 71 | 1.650 |
Why?
|
| Humans | 38 | 2025 | 5485 | 1.610 |
Why?
|
| Atropine | 4 | 2023 | 9 | 1.550 |
Why?
|
| Eyeglasses | 6 | 2022 | 30 | 1.440 |
Why?
|
| Axial Length, Eye | 2 | 2025 | 25 | 1.360 |
Why?
|
| Adult | 18 | 2024 | 1687 | 1.190 |
Why?
|
| Male | 23 | 2025 | 2770 | 1.070 |
Why?
|
| Female | 23 | 2025 | 2816 | 1.070 |
Why?
|
| Astigmatism | 2 | 2023 | 35 | 1.050 |
Why?
|
| Young Adult | 13 | 2024 | 852 | 0.970 |
Why?
|
| Child | 13 | 2025 | 657 | 0.970 |
Why?
|
| Color Vision | 2 | 2023 | 11 | 0.920 |
Why?
|
| Lens, Crystalline | 1 | 2023 | 34 | 0.850 |
Why?
|
| Age of Onset | 1 | 2023 | 3 | 0.840 |
Why?
|
| Orthokeratologic Procedures | 2 | 2021 | 9 | 0.830 |
Why?
|
| Contact Lens Solutions | 3 | 2016 | 8 | 0.800 |
Why?
|
| Aberrometry | 2 | 2017 | 8 | 0.720 |
Why?
|
| Hyperopia | 1 | 2020 | 15 | 0.710 |
Why?
|
| Adolescent | 9 | 2025 | 806 | 0.670 |
Why?
|
| Optics and Photonics | 1 | 2019 | 21 | 0.650 |
Why?
|
| Asthenopia | 1 | 2019 | 1 | 0.630 |
Why?
|
| Oculomotor Muscles | 1 | 2019 | 15 | 0.620 |
Why?
|
| Prosthesis Design | 2 | 2018 | 27 | 0.590 |
Why?
|
| Retina | 3 | 2022 | 130 | 0.580 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 97 | 0.540 |
Why?
|
| Patient Comfort | 1 | 2016 | 3 | 0.530 |
Why?
|
| Ocular Physiological Phenomena | 1 | 2016 | 6 | 0.530 |
Why?
|
| Choroid | 1 | 2016 | 25 | 0.530 |
Why?
|
| Vision Tests | 4 | 2022 | 50 | 0.520 |
Why?
|
| Mydriatics | 3 | 2023 | 11 | 0.480 |
Why?
|
| Tomography, Optical Coherence | 1 | 2016 | 217 | 0.450 |
Why?
|
| Anterior Chamber | 1 | 2013 | 7 | 0.420 |
Why?
|
| Visual Fields | 1 | 2013 | 67 | 0.410 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 350 | 0.400 |
Why?
|
| Pupil | 3 | 2023 | 45 | 0.360 |
Why?
|
| Cornea | 1 | 2013 | 140 | 0.360 |
Why?
|
| Biometry | 2 | 2025 | 32 | 0.340 |
Why?
|
| Equipment Design | 2 | 2020 | 74 | 0.330 |
Why?
|
| Middle Aged | 6 | 2019 | 1100 | 0.310 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 277 | 0.280 |
Why?
|
| Cross-Over Studies | 4 | 2021 | 31 | 0.270 |
Why?
|
| Eye | 2 | 2024 | 20 | 0.270 |
Why?
|
| Eyelids | 2 | 2016 | 10 | 0.270 |
Why?
|
| Quality of Life | 3 | 2023 | 117 | 0.250 |
Why?
|
| Withholding Treatment | 1 | 2025 | 6 | 0.240 |
Why?
|
| Prosthesis Fitting | 3 | 2021 | 23 | 0.240 |
Why?
|
| Contrast Sensitivity | 2 | 2022 | 64 | 0.230 |
Why?
|
| Ophthalmic Solutions | 1 | 2023 | 7 | 0.220 |
Why?
|
| Patient Satisfaction | 3 | 2022 | 28 | 0.220 |
Why?
|
| Vision, Low | 1 | 2022 | 2 | 0.200 |
Why?
|
| Single-Blind Method | 2 | 2021 | 12 | 0.200 |
Why?
|
| Refractometry | 1 | 2020 | 5 | 0.180 |
Why?
|
| Aged | 4 | 2016 | 860 | 0.170 |
Why?
|
| Equipment Contamination | 2 | 2016 | 3 | 0.170 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 5 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 23 | 0.160 |
Why?
|
| Corneal Wavefront Aberration | 1 | 2019 | 35 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 6 | 0.150 |
Why?
|
| Electromyography | 1 | 2019 | 47 | 0.150 |
Why?
|
| ROC Curve | 1 | 2017 | 31 | 0.140 |
Why?
|
| Retrospective Studies | 1 | 2019 | 382 | 0.140 |
Why?
|
| Organ Size | 1 | 2016 | 31 | 0.140 |
Why?
|
| Biguanides | 1 | 2016 | 3 | 0.130 |
Why?
|
| Gram-Positive Bacteria | 1 | 2016 | 3 | 0.130 |
Why?
|
| Propylamines | 1 | 2016 | 4 | 0.130 |
Why?
|
| Staining and Labeling | 1 | 2016 | 9 | 0.130 |
Why?
|
| Gram-Negative Bacteria | 1 | 2016 | 7 | 0.130 |
Why?
|
| Meibomian Glands | 1 | 2016 | 4 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 42 | 0.130 |
Why?
|
| Eyelid Diseases | 1 | 2016 | 5 | 0.130 |
Why?
|
| Macula Lutea | 1 | 2016 | 17 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2020 | 212 | 0.130 |
Why?
|
| Proteins | 1 | 2016 | 46 | 0.130 |
Why?
|
| Polymers | 1 | 2016 | 42 | 0.130 |
Why?
|
| Tropicamide | 1 | 2014 | 2 | 0.120 |
Why?
|
| Double-Blind Method | 3 | 2020 | 34 | 0.110 |
Why?
|
| Interferometry | 1 | 2013 | 6 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2013 | 21 | 0.100 |
Why?
|
| Esotropia | 1 | 2012 | 2 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2012 | 20 | 0.100 |
Why?
|
| Time Factors | 2 | 2023 | 176 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 148 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 13 | 0.050 |
Why?
|
| Vision, Binocular | 1 | 2023 | 51 | 0.050 |
Why?
|
| Africa | 1 | 2022 | 1 | 0.050 |
Why?
|
| Vision, Ocular | 1 | 2022 | 33 | 0.050 |
Why?
|
| Glare | 1 | 2021 | 2 | 0.050 |
Why?
|
| Light | 1 | 2021 | 43 | 0.040 |
Why?
|
| Ohio | 1 | 2020 | 3 | 0.040 |
Why?
|
| Sample Size | 1 | 2020 | 3 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 60 | 0.040 |
Why?
|
| Texas | 1 | 2020 | 190 | 0.040 |
Why?
|
| Internationality | 1 | 2019 | 6 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 2016 | 13 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 21 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2016 | 132 | 0.030 |
Why?
|